The price of shares in Rubis is close to a major medium term resistance level around 41.5 EUR. A correction phase over the short term appears to be the logical outcome. Investors should open a short trade and target the € 38.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
The company is one of the best yield companies with high dividend expectations.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Technically, the stock approaches a strong medium-term resistance at EUR 41.5.
As estimated by analysts, this group is among those businesses with the lowest growth prospects.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.